Drug Profile


Alternative Names: Anti CA125 Mab oregovomab; B43.13; Mab B43.13; Monoclonal antibody B43.13; OvaRex

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator AltaRex
  • Developer National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 07 Dec 2016 Phase-II clinical trials in Ovarian cancer (Recurrent, Combination therapy) in USA (IV)
  • 07 Dec 2016 OncoQuest plans a phase III trial for Ovarian cancer
  • 22 Mar 2016 Oregovomab licensed to Shenzhen Hepalink Pharmaceutical in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top